metabolism, immunometabolism, innate immunity, macrophage
Our laboratory conducts studies of the regulation of innate immune cells. We utilize in vitro biochemical approaches, metabolomics, metabolic flux analysis, heavy isotope tracing, and animal models to dissect metabolic pathways in cells of the innate immune system. The laboratory currently has projects running investigating metabolic control of NK cells, monocytes/macrophages and neutrophils. In addition, as part of the NCI Cancer and Inflammation Program (CIP), we translate these projects into in vivo models of inflammation and carcinogenesis. The CIP is a multidisciplinary program of investigators with expertise in metabolism, cancer models, signaling, molecular biology, genetics, the microbiome, and inflammation, providing trainees with a broad range of collaborative training opportunities. This position is available spring/summer 2018 and candidates will be considered until the position is filled.
The NCI-Frederick campus is located about 40 miles northwest of Washington DC in the foothills of the Blue Ridge Mountains. The campus houses scores of NCI principal investigators, state-of-the-art animal facilities, and the NCI mass spectrometry, genetics, transgene, knockout, and germ-free cores, but is just minutes from recreational opportunities on the Appalachian Trail and the Potomac and Shenandoah Rivers.
Applicants must have a Ph.D. and/or M.D. and less than five years of postdoctoral experience. Demonstrable knowledge and experience in the biochemistry of metabolism is beneficial. Experience with the methods, technologies (LC-MS, NMR etc.), and datasets associated with metabolic studies is highly recommended.
To be considered, candidates must submit: 1) a CV, 2) statement of research experience and career goals, 3) contact information for three references, and 4) a brief (1-2 page) description of proposed lines of inquiry that build on current themes in immunometabolism. Please apply to:
Daniel McVicar, Ph.D.
Head, Leukocyte Signaling Section
HHS, NIH, and NCI are Equal Opportunity Employers